

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

NCT06823375

Status	RECRUITING
Phase	Phase 2
Sponsor	Chinese University of Hong Kong
Enrollment	40 participants

Key Eligibility Criteria

Inclusion (16)

- Patients aged ≥ 18 years old
 - ECOG performance 0 to 1
 - Confirmed diagnosis of HCC (either histologic or cytologic analysis, or clinical features according to the American Association for the Study of Liver Diseases)
 - Presence of major portal vein thrombosis (Vp3 [first-order tumour thrombosis in portal vein] or Vp4 [tumour thrombosis in the main portal vein, or portal vein branch in contralateral lobe]), limited to the liver and should be amenable to SBRT
 - No disease progression after 2 cycles of atezolizumab plus bevacizumab
- ... and 11 more (see full listing online)

Exclusion (12)

- History of another malignancy except appropriately-treated BCC of skin or CIN of cervix during the last 5 years
 - History of rupture HCC in the past 3 months
 - History of gastric or esophageal varices with interventions performed within 1 month
 - Tumour thrombosis that extends beyond the portal vein (e.g. inferior vena cava, superior vena cava)
 - Liver tumours occupy ≥ 50% of liver
- ... and 7 more (see full listing online)

Locations (2 total)

Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, Hong Kong
Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, Hong Kong